Article
Pharmacology & Pharmacy
Yu Yoshida, Sayaka Sasaoka, Mizuki Tanaka, Kiyoka Matsumoto, Misaki Inoue, Riko Satake, Kazuyo Shimada, Ririka Mukai, Takaaki Suzuki, Mari Iwata, Fumiya Goto, Takayuki Mori, Koki Mori, Tomoaki Yoshimura, Mitsuhiro Nakamura
Summary: This study assessed the clinical features of hand-foot syndrome (HFS) associated with certain systemic chemotherapeutic drugs using the Japanese Adverse Drug Event Report (JADER) database. The results revealed a potential risk of HFS with specific drugs and emphasized the importance of careful observation during treatment.
THERAPEUTIC ADVANCES IN DRUG SAFETY
(2022)
Article
Pharmacology & Pharmacy
Xiang Zhou, Xiaofei Ye, Xiaojing Guo, Dongxu Liu, Jinfang Xu, Fangyuan Hu, Yinghong Zhai, Yongqing Gao, Xiao Xu, Ziwei Dong, Jia He
Summary: The study investigated the distribution of adverse events related to SGLT2 inhibitors in different systems and identified important medical event signals. Most SGLT2 inhibitor-related important medical events occurred during monotherapy, with common strong signals including diabetic ketoacidosis and ketoacidosis. Unexpected safety signals such as cellulitis and nephrolithiasis were detected.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Donald C. Moore, Joseph B. Elmes, Justin R. Arnall, Scott A. Strassels, Jai N. Patel
Summary: Immune checkpoint inhibitors (ICIs) used for cancer treatment can increase the risk of rare autoimmune hematologic toxicities, including acquired thrombotic thrombocytopenic purpura (TTP). This retrospective observational analysis found a significant association between several ICIs and TTP, highlighting the importance of monitoring for this potentially life-threatening adverse event in clinical practice.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Milton Packer, Christopher S. S. Wilcox, Jeffrey M. M. Testani
Summary: SGLT2 inhibitors have complex effects on renal tubule function and volume homeostasis, with limited diuretic and natriuretic effects. However, they may result in durable improvement of the internal set point for volume homeostasis. These drugs also exert cardioprotective effects through direct actions on cardiomyocytes. The interplay between changes in volume set point and the direct cellular effects may contribute to the benefits of SGLT2 inhibitors in heart failure.
Article
Public, Environmental & Occupational Health
Yamin Shu, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang
Summary: Through data mining analysis, this study identified olaparib-associated adverse events consistent with clinical observations. Additionally, potential new and unexpected adverse event signals were discovered, highlighting the need for further clinical studies to confirm and elucidate these findings.
CLINICAL EPIDEMIOLOGY
(2022)
Article
Pharmacology & Pharmacy
Lei Zhang, Chen Pan, Xinyu Yang, Dechun Jiang, Mingnan Cao
Summary: This study systematically examined the association between Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and cardiac adverse events (CAEs). The results showed no association between SGLT2i and the reporting frequencies of CAEs, except for myocardial infarction. Additionally, SGLT2i-associated CAEs were associated with 11.33% fatality and 51.25% hospitalization.
EXPERT OPINION ON DRUG SAFETY
(2023)
Article
Biochemistry & Molecular Biology
Rui Hu, Anita Layton
Summary: The study investigates how kidney function is altered in patients with diabetes and the renal effects of an anti-hyperglyceamic therapy that inhibits SGLT2. Results indicate that SGLT2 inhibition may attenuate glomerular hyperfiltration and reduce single-nephron glomerular filtration rate.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cardiac & Cardiovascular Systems
Tsung-Kun Lin, Yong-Hsin Chen, Jing-Yang Huang, Pei-Lun Liao, Mei-Chun Chen, Lung-Fa Pan, Gwo-Ping Jong
Summary: This study aims to determine the association between the use of SGLT2 inhibitors and new-onset stroke (NOS) in patients with type 2 diabetes mellitus. The results showed that the risk of NOS was lower in SGLT2 inhibitor users compared to non-SGLT2 inhibitor users.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Multidisciplinary Sciences
Richard Osei Buabeng, Paul Dsane-Aidoo, Yaw K. Asamoah, Delia Akosua Bandoh, Yvonne Adu Boahen, George Tsey Sabblah, Delese Mimi Darko, Charles Noora Lwanga, Donne Kofi Ameme, Ernest Kenu
Summary: This study evaluated the ADRSS in the Ho Municipality in Ghana and found that there was under-reporting of ADRs. The ADRSS showed strengths in certain aspects, but there were still issues with flexibility and timeliness.
Article
Biology
Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu
Summary: This study conducted a comprehensive survey of adverse events (AEs) of two PARP inhibitors, olaparib and niraparib, using a Japanese database. The results suggest the importance of early response and monitoring in PARP inhibitor therapy, and provide suggestions for managing side effects and offering supportive care.
Article
Biochemistry & Molecular Biology
Kazufumi Nakamura, Toru Miyoshi, Masashi Yoshida, Satoshi Akagi, Yukihiro Saito, Kentaro Ejiri, Naoaki Matsuo, Keishi Ichikawa, Keiichiro Iwasaki, Takanori Naito, Yusuke Namba, Masatoki Yoshida, Hiroki Sugiyama, Hiroshi Ito
Summary: There is a strong correlation between diabetes mellitus and heart failure, with diabetes serving as an independent risk factor for heart failure. The link between diabetes and heart failure is not only due to complications such as ischemic heart disease, but also metabolic disorders like glucose toxicity and lipotoxicity caused by insulin resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Endocrinology & Metabolism
Pierre Delanaye, Andre J. Scheen
Summary: SGLT2is are a new class of oral glucose-lowering agents that provide cardiovascular and renal protection, with unclear diuretic effects that exhibit favorable properties such as reduced sympathetic activity and preserved potassium balance.
DIABETES & METABOLISM
(2021)
Article
Pharmacology & Pharmacy
Li Wang, Bin Zhao
Summary: This study aimed to establish the association between Janus kinase inhibitors therapy and the adverse event of pemphigus in patients with rheumatologic and inflammatory disorders. A disproportionality analysis using the FDA Adverse Event Reporting System revealed 3,032 pemphigus reports associated with two Janus kinase inhibitors, with a significant signal detected in the Tofacitinib group. High-risk individuals were identified as female, aged 40-49, or with rheumatoid arthritis. Rheumatology and dermatology specialists should exercise increased vigilance in clinical practice to benefit these patients.
EXPERT OPINION ON DRUG SAFETY
(2023)
Article
Surgery
Eun Jeong Ko, Yoo Jin Shin, Sheng Cui, Sun Woo Lim, Byung Ha Chung, Chul Woo Yang
Summary: This study evaluated the effects of SGLT2i and DPP4i in TAC-induced diabetes and nephrotoxicity. The results showed that the combination of SGLT2i and DPP4i was more effective in reducing blood glucose levels, improving pancreatic islet function, and enhancing renal function compared to using each drug alone. Additionally, the combination therapy significantly reduced oxidative stress.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Neurosciences
Kenichiro Sato, Tatsuo Mano, Atsushi Iwata, Tatsushi Toda
Summary: Through an analysis of the JADER database, it was found that there is no statistically robust evidence to support an increase in neuropsychiatric adverse events with the combination of memantine and specific drugs like amantadine or dextromethorphan in real-world data.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Review
Clinical Neurology
Harald Hampel, Leslie M. Shaw, Paul Aisen, Christopher Chen, Alberto Lleo, Takeshi Iwatsubo, Atsushi Iwata, Masahito Yamada, Takeshi Ikeuchi, Jianping Jia, Huali Wang, Charlotte E. Teunissen, Elaine Peskind, Kaj Blennow, Jeffrey Cummings, Andrea Vergallo
Summary: The article discusses the necessity and inconsistency of lumbar puncture in the diagnosis of Alzheimer's disease, highlighting the importance of lumbar puncture in early diagnosis and treatment.
ALZHEIMERS & DEMENTIA
(2022)
Article
Cardiac & Cardiovascular Systems
Kenichiro Sato, Atsushi Iwata, Masanori Kurihara, Tatsuo Mano, Tatsushi Toda
Summary: The study found significantly higher reporting odds ratios (ROR) for stress cardiomyopathy (TTS) following the use of certain adrenergic drugs, predominantly in women and patients in their 70s. The results suggest a potential association of taking midodrine or droxidopa with the development of TTS.
JOURNAL OF CARDIOLOGY
(2022)
Letter
Cardiac & Cardiovascular Systems
Kenichiro Sato, Atsushi Iwata, Masanori Kurihara, Tatsuo Mano, Tatsushi Toda
JOURNAL OF CARDIOLOGY
(2022)
Article
Clinical Neurology
Tomoyasu Matsubara, Masashi Kameyama, Noriko Tanaka, Renpei Sengoku, Makoto Orita, Ko Furuta, Atsushi Iwata, Tomio Arai, Hirofumi Maruyama, Yuko Saito, Shigeo Murayama
Summary: This study validates the diagnostic accuracy of I-123-MIBG myocardial scintigraphy for Lewy body diseases against autopsy, demonstrating its ability to differentiate LBDs from similar diseases. Abnormal findings strongly support the presence of LBD and cardiac sympathetic denervation. However, normal myocardial scintigraphy results should not exclude LBD pathology, especially when comorbid Alzheimer disease pathology is suggested by other biomarkers.
Article
Biology
Kenichiro Sato, Yoshiki Niimi, Tatsuo Mano, Atsushi Iwata, Takeshi Iwatsubo
Summary: This study investigated the time to onset of drug-induced parkinsonism (DIP) depending on the type of drugs causing DIP using a large real-world database. The results showed that the characteristics of the time to onset of DIP significantly differed depending on the type of drug, which is important for diagnosing patients with parkinsonism.
Article
Clinical Neurology
Kenichiro Sato, Yoshiki Niimi, Tatsuo Mano, Atsushi Iwata, Takeshi Iwatsubo
Summary: This study demonstrates the feasibility of using a deep neural network model based on the Clock-Drawing Test to automatically detect cognitive decline in a large cohort of older adults, suggesting its potential as a mass screening tool for identifying individuals with executive dysfunction or probable dementia.
FRONTIERS IN NEUROLOGY
(2022)
Article
Multidisciplinary Sciences
Koyo Tsujikawa, Kohei Hamanaka, Yuichi Riku, Yuki Hattori, Norikazu Hara, Yohei Iguchi, Shinsuke Ishigaki, Atsushi Hashizume, Satoko Miyatake, Satomi Mitsuhashi, Yu Miyazaki, Mayumi Kataoka, Li Jiayi, Keizo Yasui, Satoshi Kuru, Haruki Koike, Kenta Kobayashi, Naruhiko Sahara, Norio Ozaki, Mari Yoshida, Akiyoshi Kakita, Yuko Saito, Yasushi Iwasaki, Akinori Miyashita, Takeshi Iwatsubo, Takeshi Ikeuchi, Takaki Miyata, Gen Sobue, Naomichi Matsumoto, Kentaro Sahashi, Masahisa Katsuno
Summary: This study identified the role of Filamin-A in promoting tau aggregation in progressive supranuclear palsy (PSP) patients without tau mutations. It found that nonmutated tau interacts with actin filaments through increased levels of Filamin-A, resulting in enhanced phosphorylation and insolubility of tau. The study also showed that reducing Filamin-A levels corrected aberrant tau levels in PSP cell cultures.
Article
Clinical Neurology
Kazuto Yamashita, Masahiro Miura, Shunsuke Watanabe, Kengo Ishiki, Yuji Arimatsu, Junko Kawahira, Toshiko Kubo, Katsutaka Sasaki, Takayuki Arai, Kei Hagino, Yasuhiro Irino, Kota Nagai, David Verbel, Akihiko Koyama, Shobha Dhadda, Hayato Niiro, Shigeki Iwanaga, Toshiyuki Sato, Tomokazu Yoshida, Atsushi Iwata
Summary: The measurement of plasma Aβ42/Aβ40 ratio can accurately predict amyloid PET status, with high sensitivity and specificity. This method is less invasive and more accessible compared to amyloid PET and cerebrospinal fluid testing.
ALZHEIMERS RESEARCH & THERAPY
(2022)
Article
Clinical Neurology
Harald Hampel, Aya Elhage, Leslie M. Shaw, Paul Aisen, Christopher Chen, Alberto Lleo, Takeshi Iwatsubo, Atsushi Iwata, Masahito Yamada, Takeshi Ikeuchi, Jianping Jia, Huali Wang, Charlotte E. Teunissen, Elaine Peskind, Kaj Blennow, Jeffrey Cummings, Andrea Vergallo
Summary: This article is a summary of the safe use of lumbar puncture in diagnosing Alzheimer's disease and other forms of dementia. Despite the low risk of complications, there may be reluctance among physicians and patients to recommend or undergo this procedure. Patient education, specialist training, and new methods for patient safety are important factors in supporting the widespread use of lumbar puncture in Alzheimer's disease.
NEURODEGENERATIVE DISEASE MANAGEMENT
(2022)
Letter
Geriatrics & Gerontology
Keiko Hatano, Yasushi Nishina, Kazutomi Kanemaru, Atsushi Iwata
GERIATRICS & GERONTOLOGY INTERNATIONAL
(2022)
Article
Cell Biology
Harald Hampel, Rhoda Au, Soeren Mattke, Wiesje M. M. van der Flier, Paul Aisen, Liana Apostolova, Christopher Chen, Min Cho, Susan De Santi, Peng Gao, Atsushi Iwata, Ricky Kurzman, Andrew J. J. Saykin, Stefan Teipel, Bruno Vellas, Andrea Vergallo, Huali Wang, Jeffrey Cummings
Summary: This Perspective discusses the reconceptualization of Alzheimer's disease as a clinical and biological construct and proposes a new framework for clinical care pathways that incorporates biomarker-guided and digitally facilitated decision-making algorithms. The challenges and potential solutions for this transformation are addressed.
Article
Clinical Neurology
Kensaku Kasuga, Masataka Kikuchi, Tamao Tsukie, Kazushi Suzuki, Ryoko Ihara, Atsushi Iwata, Norikazu Hara, Akinori Miyashita, Ryozo Kuwano, Takeshi Iwatsubo, Takeshi Ikeuchi
Summary: The AT(N) classification aids in understanding the significance of Alzheimer's disease continuum biology in various populations, as it can categorize individuals based on different biomarkers.
BMJ NEUROLOGY OPEN
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kenji Ishibashi, Yoshiharu Miura, Tetsuro Tago, Jun Toyohara, Mana Higashihara, Atsushi Iwata, Kenji Ishii
Summary: This study examined the distribution pattern of F-18-THK5351 in the healthy brain and found that its uptake largely reflects the concentrations of MAO-B under normal conditions.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Cell Biology
Takayuki Kondo, Norikazu Hara, Satoshi Koyama, Yuichiro Yada, Kayoko Tsukita, Ayako Nagahashi, Takeshi Ikeuchi, Kenji Ishii, Takashi Asada, Tetsuaki Arai, Ryo Yamada, Haruhisa Inoue
Summary: This study identified 24 significant genome-wide loci associated with alterations in amyloid beta production in Alzheimer's disease through a cellular dissection of polygenicity approach. The findings improve the predictions of amyloid positivity in the brains and cerebrospinal fluid of patients with Alzheimer's disease.
Article
Biochemistry & Molecular Biology
Naoki Watanabe, Masaki Nakano, Yachiyo Mitsuishi, Norikazu Hara, Tatsuo Mano, Atsushi Iwata, Shigeo Murayama, Toshiharu Suzuki, Takeshi Ikeuchi, Masaki Nishimura
Summary: The study revealed that the downregulation of FAM3C in the AD brain may be a risk factor for A beta accumulation and eventually AD development. Transcriptional mechanisms involving SP1, EBF1, SMAD1, and KLF6 were identified as factors influencing the expression of FAM3C, with reduced nuclear levels of SP1 and EBF1 in AD brains contributing to the observed transcriptional downregulation.
HUMAN MOLECULAR GENETICS
(2022)